CEO, Arecor and Chair of the EuropaBio SME platform
Tom Saylor is an experienced CEO with a proven track record of building and managing
entrepreneurial organizations. His experience includes fundraising, strategy development, inand
out-licensing, and acquisitions in Asia, Europe and the United States.
He is currently CEO
of Arecor Limited, a British company focused upon enabling the next generation of therapeutic
proteins and vaccines through advanced formulation technologies. Previously, he was CEO of
Sirus Limited, a drug targeting and delivery company based in Cambridge, England. Prior to
joining Sirus, Tom was Chairman and founder of Lotus Healthcare Corporation, an Asian-based
fully ntegrated pharmaceutical company.
Tom built Lotus Healthcare from a small marketing
group into a fully integrated producer and marketer of analgesics, cardiovascular and GI
products with two GMP manufacturing sites and a sales staff of 100 representatives covering the
top 35 cities of China.
Tom was also Chief Executive Officer of Cell Systems Limited, a company
focusing on medical applications of cryopreservation and algal biotechnology. Previously, Tom
was Executive Vice President of a multi-billion dollar diversified industrial and financial group
based in New York.
He held a ministerial appointment and was a prinicipal negotiator in the
Tokyo Round of multilateral trade negotiations for the United States.
Tom is Chairman of the SME Platform, a member of the board of EuropaBio and the Executive
Committee of the British North American Committee.
Tom holds an MBA from Harvard University, undertook doctoral studies in molecular biology at
the Max Planck Institute for Psychiatry in Munich and holds a degree in molecular biology from
the Georgia Institute of Technology.
- The Policy Environment for Improving Access to Finance for Biotech SME's
- Mitigating rise by leveraging public grant programs
- Importance of tax policy for entrepeneurs
- Enterprise & Investors
- Regulatory policies and their impact on risk/uncertainty
- Building towards a common market in healthcare